Compass Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(In thousands)
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at December 31, 2024 | 137,820 | $14 | $489,692 | $210 | $(364,683) | $125,233 |
| Stock-based awards, net of tax remittance | 462 | — | (815) | — | — | (815) |
| Stock-based compensation | — | — | 2,514 | — | — | 2,514 |
| Unrealized loss on marketable securities | — | — | — | (20) | — | (20) |
| Net loss | — | — | — | — | (16,633) | (16,633) |
| Balance at March 31, 2025 | 138,282 | 14 | 491,391 | 190 | (381,316) | 110,279 |
| Stock-based compensation | — | — | 2,791 | — | — | 2,791 |
| Unrealized loss on marketable securities | — | — | — | 18 | — | 18 |
| Net loss | — | — | — | — | (19,881) | (19,881) |
| Balance at June 30, 2025 | 138,282 | $14 | $494,182 | $208 | $(401,197) | $93,207 |
| Common stock and warrants issued, net of costs of $8.6 million | 39,290 | 39 | 129,322 | — | — | 129,361 |
| Stock-based compensation | — | — | 1,238 | — | — | 1,238 |
| Unrealized loss on marketable securities | — | — | — | 66 | — | 66 |
| Net loss | — | — | — | — | (14,259) | (14,259) |
| Balance at September 30, 2025 | 177,572 | $53 | $624,742 | $274 | $(415,456) | $209,613 |
| Balance at December 31, 2023 | 127,668 | $13 | $463,796 | $37 | $(315,308) | $148,538 |
| Common stock issued, net of costs of $0.5 million | 9,790 | 1 | 17,568 | — | — | 17,569 |
| Stock-based awards, net of tax remittance | 131 | — | (136) | — | — | (136) |
| Stock-based compensation | — | — | 2,003 | — | — | 2,003 |
| Unrealized loss on marketable securities | — | — | — | (127) | — | (127) |
| Net loss | — | — | — | — | (10,787) | (10,787) |
| Balance at March 31, 2024 | 137,589 | 14 | 483,231 | (90) | (326,095) | 157,060 |
| Stock-based compensation | — | — | 2,121 | — | — | 2,121 |
| Unrealized loss on marketable securities | — | — | — | (1) | — | (1) |
| Net loss | — | — | — | — | (13,076) | (13,076) |
| Balance at June 30, 2024 | 137,589 | $14 | $485,352 | $(91) | $(339,171) | $146,104 |
| Stock-based compensation | — | — | 2,198 | — | — | 2,198 |
| Unrealized gain on marketable securities | — | — | — | 577 | — | 577 |
| Net loss | — | — | — | — | (10,481) | (10,481) |
| Balance at September 30, 2024 | 137,589 | $14 | $487,550 | $486 | $(349,652) | $138,398 |
**Condensed Consolidated Statements of Cash Flows (Unaudited)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.